Telix ADRs Fall After Company Discloses SEC Subpoena

Dow Jones

Jul 24, 2025

By Dean Seal

Telix Pharmaceuticals' American depositary receipts dropped after the company disclosed that it has received a subpoena from the Securities and Exchange Commission.

The ADRs were down 10% at $1.60 in afternoon trading. They are now down 5% year to date.

The Melbourne, Australia-based company said in its second-quarter earnings report that the U.S. securities regulator is seeking various documents and information related to disclosures about the development of Telix's prostate-cancer therapeutic candidates.

Telix said it is fully cooperating with the SEC and in the process of responding to its request.

"At this stage, this matter is a fact-finding request," the company said.

The company has elected to notify the Australian Securities and Investments Commission about the SEC's inquiry. While the matter is ongoing, Telix plans to continue with its clinical-development programs related to its prostate-cancer therapy candidates.

Write to Dean at dean.seal@wsj.com

(END) Dow Jones Newswires

July 23, 2025 12:55 ET (16:55 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2553244422"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553244422\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553244422?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-24 00:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553244422","market":"hk","top_or_hot":-1,"title":"Telix ADRs Fall After Company Discloses SEC Subpoena","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a>' <a href=\"https://laohu8.com/S/AFG\">American</a> depositary receipts dropped after the company disclosed that it has received a subpoena from the Securities and Exchange Commission. \n</p>\n<p>\n  The ADRs were down 10% at $1.60 in afternoon trading. They are now down 5% year to date. \n</p>\n<p>\n  The Melbourne, Australia-based company said in its second-quarter earnings report that the U.S. securities regulator is seeking various documents and information related to disclosures about the development of Telix's prostate-cancer therapeutic candidates. \n</p>\n<p>\n  Telix said it is fully cooperating with the SEC and in the process of responding to its request. \n</p>\n<p>\n  \"At this stage, this matter is a fact-finding request,\" the company said. \n</p>\n<p>\n  The company has elected to notify the Australian Securities and Investments Commission about the SEC's inquiry. While the matter is ongoing, Telix plans to continue with its clinical-development programs related to its prostate-cancer therapy candidates. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 23, 2025 12:55 ET (16:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Telix ADRs Fall After Company Discloses SEC Subpoena</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTelix ADRs Fall After Company Discloses SEC Subpoena\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-24 00:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a>' <a href=\"https://laohu8.com/S/AFG\">American</a> depositary receipts dropped after the company disclosed that it has received a subpoena from the Securities and Exchange Commission. \n</p>\n<p>\n  The ADRs were down 10% at $1.60 in afternoon trading. They are now down 5% year to date. \n</p>\n<p>\n  The Melbourne, Australia-based company said in its second-quarter earnings report that the U.S. securities regulator is seeking various documents and information related to disclosures about the development of Telix's prostate-cancer therapeutic candidates. \n</p>\n<p>\n  Telix said it is fully cooperating with the SEC and in the process of responding to its request. \n</p>\n<p>\n  \"At this stage, this matter is a fact-finding request,\" the company said. \n</p>\n<p>\n  The company has elected to notify the Australian Securities and Investments Commission about the SEC's inquiry. While the matter is ongoing, Telix plans to continue with its clinical-development programs related to its prostate-cancer therapy candidates. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 23, 2025 12:55 ET (16:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2553244422","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553244422","pubTimestamp":1753289700,"columns":[{"name":"Policy And Regulatory","id":32,"label_key":"policyRegulatory"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Telix Pharmaceuticals' American depositary receipts dropped after the company disclosed that it has received a subpoena from the Securities and Exchange Commission.The ADRs were down 10% at $1.60 in afternoon trading. They are now down 5% year to date.The Melbourne, Australia-based company said in its second-quarter earnings report that the U.S. securities regulator is seeking various documents and information related to disclosures about the development of Telix's prostate-cancer therapeutic candidates.Telix said it is fully cooperating with the SEC and in the process of responding to its request.\"At this stage, this matter is a fact-finding request,\" the company said.The company has elected to notify the Australian Securities and Investments Commission about the SEC's inquiry. While the matter is ongoing, Telix plans to continue with its clinical-development programs related to its prostate-cancer therapy candidates.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","TLX.AU":"TELIX PHARMACEUTICALS LTD"},"translate_title":"Telix ADR在公司披露SEC传票后下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX.AU":0.9},"content_text":"By Dean Seal \n\n\n \n\n\nTelix Pharmaceuticals' American depositary receipts dropped after the company disclosed that it has received a subpoena from the Securities and Exchange Commission. \n\n\n  The ADRs were down 10% at $1.60 in afternoon trading. They are now down 5% year to date. \n\n\n  The Melbourne, Australia-based company said in its second-quarter earnings report that the U.S. securities regulator is seeking various documents and information related to disclosures about the development of Telix's prostate-cancer therapeutic candidates. \n\n\n  Telix said it is fully cooperating with the SEC and in the process of responding to its request. \n\n\n  \"At this stage, this matter is a fact-finding request,\" the company said. \n\n\n  The company has elected to notify the Australian Securities and Investments Commission about the SEC's inquiry. While the matter is ongoing, Telix plans to continue with its clinical-development programs related to its prostate-cancer therapy candidates. \n\n\n \n\n\n  Write to Dean at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 23, 2025 12:55 ET (16:55 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}